98%
921
2 minutes
20
Introduction: Accurate evaluation of respiratory rate and pattern is important in health and disease; however, it can be challenging in children and babies due to small size and poor tolerability of existing monitoring equipment. This protocol outlines a study evaluating the feasibility of collecting respiratory data using a chest-worn accelerometer-based motion sensor in paediatric patients at risk of apnoea, respiratory failure and sudden death.
Methods And Analysis: This is an observational feasibility study over a 2-year period. The biosensor is an accelerometer worn on an ECG electrode during standard care at the Royal Hospital for Children, Glasgow. We aim to recruit three groups of patients (75 patients to each group): (1) Children attending for overnight cardiorespiratory polygraphy (0 to ≤16 years), (2) neonatal inpatients (from 30 weeks gestation) and (3) children attending for video telemetry at the epilepsy monitoring unit (0 to ≤16 years). Measurements will include (1) chest and/or abdominal wall motion measured by the worn biosensors; (2) standard clinical monitoring data will be collected to support biosensor data interpretation and (3) acceptability will be measured by a feedback questionnaire completed by patients and their parents/guardians.
Ethics And Dissemination: This study protocol was reviewed and approved by Yorkshire and The Humber-Leeds East Research Ethics Committee, approval number 314 696. This study involves human participants; written informed consent and assent, when appropriate, will be obtained from participants (or their parent/legal guardian/next of kin) to participate in the study. The study will be carried out in accordance with the World Medical Association Declaration of Helsinki (1964) standard reporting. Study findings will be reported clearly and transparently with relevant stakeholders including researchers, practitioners and publicly available databases. Results from this study will be presented at national and international conferences and reported in peer-reviewed publications.
Trial Registration Number: NCT06292299 pre-results stage.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406817 | PMC |
http://dx.doi.org/10.1136/bmjopen-2025-104363 | DOI Listing |
Pain Manag
September 2025
Pain Management Unit, Hospital Universitario Quirónsalud Madrid, Madrid, Spain.
Aims: The aim of this observational study is to describe the use of epiduroscopy to decrease the enlargement of the ligamentum flavum (LF) in patients with spinal stenosis, as well as the selection of the appropriate patient and the safety measures that enhance procedural success.
Materials & Methods: We introduce the patient selection protocol, define the appropriate indication and the safety measures to use the epiduroscopy as a tool to decrease the size of the LF and increase space, reducing possible complications.
Results: Among patients included in the study, there were no cases of access difficulty or coccydynia, and one case of urinary incontinence occurred in a patient with Schizas grade D (very severe) stenosis.
Acta Vet Hung
September 2025
4Department of Internal Medicine, University of Veterinary Medicine Budapest, István Street 2, 1078 Budapest, Hungary.
The low dose dexamethasone stimulation test (LDDST) is routinely used in canine medicine but in the few cases in guinea pigs diagnosed with hypercortisolism, the adrenocorticotropic hormone (ACTH) stimulation test was used. The objective of the authors was to conduct a pilot study and find out if the standard test used in dogs can be used in this species.A 4-year-old intact female hairless guinea pig showed bilaterally enlarged adrenal glands and high cortisol levels.
View Article and Find Full Text PDFNephrol Dial Transplant
September 2025
Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Background: We investigated circulating protein profiles and molecular pathways among various chronic kidney disease (CKD) etiologies to study its underlying molecular heterogeneity.
Methods: We conducted a proteomic biomarker analysis in the DAPA-CKD trial recruiting adults with and without type 2 diabetes with an eGFR of 25 to 75 mL/min/1.73m2 and a UACR of 200 to 5000 mg/g.